IN8bio (INAB) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
IN8bio (INAB) has outperformed TScan Therapeutics (TCRX) over the past year, losing 42.5% versus a loss of 89.0%. Over five years, TCRX leads with a -96.5% price change compared with -99.3% for INAB. TScan Therapeutics is the larger company by market cap ($16.1 million vs $13.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INAB | TCRX |
|---|---|---|
| Share price | $1.34 | $0.238 |
| Market cap | $13.21M | $16.13M |
| 1-day change | -2.90% | +4.29% |
| YTD return | -42.74% | -76.20% |
| 1-year return | -42.49% | -89.03% |
| 5-year return | -99.26% | -96.47% |
| EPS (TTM) | $-1.62 | $-0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $2.57 |
| 52-week low | $0.88 | $0.224 |
| Distance from 52-week high | -50.92% | -90.74% |
| Analyst consensus | none | hold |
| Avg. price target upside | +422.39% | +320.17% |
| Average volume | 56.80K | 782.45K |
| Shares outstanding | 9.86M | 63.50M |
| Employees | 18 | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed TCRX by 46.5 percentage points over the past year.
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
INAB vs TCRX FAQ
Which is bigger, IN8bio or TScan Therapeutics?
TScan Therapeutics (TCRX) is larger, with a market capitalization of $16.13M compared with $13.21M for IN8bio (INAB).
Which stock has performed better over the past year, INAB or TCRX?
INAB returned -42.49% over the past 12 months, compared with -89.03% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are IN8bio and TScan Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.